Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

ACC 2023: Management of Statin Side Effects and How to Keep Them on …

ACC 2023 Conference Coverage

J. Saseen

ACC 2022: How I Manage Statin-associated Muscle Symptoms and Other B…

ACC 2022 Conference Coverage

P. Toth

NLA Scientific Statement on Statin Intolerance: A New Definition and…

National Lipid Association

M. Cheeley

Treatment of Lipids in 2023: Where Are We Now and Where Are We Going?

Houston Methodist DeBakey Heart and Vascular Center

C. Ballantyne

Clear Outcomes - The First (and Only) Trial in Statin Intolerant Pat…

MUSC Cardiology

M. Budoff

Anti-Inflammatory Therapies in Cardiovascular Diseases

Penn Medicine Heart and Vascular Center

A. Abbate

LDL-C lowering and the Brain: Differentiating Fact from Fiction

ASPC 2019 Congress on CVD Prevention

P. Toth

Diagnosing Statin Intolerance

Rhonda Cooper-DeHoff

Diagnosis and Definition of Statin Intolerance

Mike Kelly

Non-Statin Therapies, Expert ACC Consensus

The Texas Heart Institute

C. Ballantyne

Non-Statin Drugs and New Approaches

Cardiometabolic Health Congress (CMHC)

M. Sabatine, C. Ballantyne

AHA 2023 Insights: Inflammation and Cholesterol as Predictors of Car…

AHA 2023 Insights

P. Ridker

ACC/AHA Cholesterol Guideline: How to Handle the High-Risk Patients

National Lipid Association

K. Birtcher

Paradigm Shifts: Understanding and Applying the Latest Lipid Guideli…

Advances in Cardiovascular Disease Prevention

A. Freeman

Management of Statin Intolerant High Risk Patients: What Are The Cur…

Cleveland Clinic European Society of Cardiology 2016 Symposium

New Drugs in Development for Dyslipidemia

National Lipid Association

Management of Statin Intolerance

Mike Kelly

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients Wit…

Cleveland Clinic Heart, Vascular and Thoracic Institute

S. Nissen

Current Treatments for LDL Lowering — and Why Patient Access Is So I…

The North American Thrombosis Forum (NATF)

J. Plutzky, H. Johnson, S. Martin